Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: Impact and implications

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 1, 2010, Pages 73-85

  McGinn, Diane ^a   Godman, Brian ^b,c,d   Lonsdale, Julie ^a   Way, Rosalind ^a   Wettermark, Bjrn ^d   Haycox, Alan ^c  

^a NHS North Lancashire   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Generics; Pharmaceutical reform; Proton pump inhibitor; Statins; Targets; UK

Indexed keywords

ATORVASTATIN; ESOMEPRAZOLE; EZETIMIBE; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; OMEPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN; AZETIDINE DERIVATIVE;

AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; HUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; QUALITY CONTROL; REIMBURSEMENT; UNITED KINGDOM; CLINICAL PRACTICE; ECONOMICS; HEALTH CARE QUALITY; NATIONAL HEALTH SERVICE; STANDARD;

AMBULATORY CARE; AZETIDINES; DRUGS, GENERIC; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH, REIMBURSEMENT; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; QUALITY ASSURANCE, HEALTH CARE; STATE MEDICINE;

EID: 77950896280     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.09.73     Document Type: Article

References (56)

1. Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden-implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550 (2008).
2. Godman B, Wettermark B, Hoffmann M, Andersson K, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 65-83 (2009).
3. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: Offce of Fair Trading proposal for funding new drugs to beneft patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008).
4. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and effciency of prescribing of proton pump inhibitors and lipid lowering drugs. Pharmacoeconomics 27, 1-4 (2009).
5. Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy 8(1), 7-24 (2010).
6. Godman B, Bucsics A, Burkhardt T, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoeconomics Outcomes Res. 8, 357-371 (2008).
7. Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth 14(2), 18-22 (2008).
8. Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J. Gen. Med. 4, 4-14 (2006).
9. Coma A, Zara C, Godman B et al. Policies to enhance the effciency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 569-581 (2009).
10. Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare? Expert Rev. Pharmacoeconomics Outcomes Res. 8(6), 549-555 (2008).
11. Duerden M. Making sense of Drug Pricing. Prescriber supplement. John Wiley & Sons Ltd. West Sussex, UK (2006).
12. Chaplin S, Duerdin M. When Brands are Best: Brand vs. Generic Prescribing: Prescriber Guide. Wiley Interface Ltd, NJ, USA (2006).
13. Gilley J. Towards rational prescribing. BMJ 308, 731-732 (1994).
14. Mason AR, Drummond MF, Hunter JA, Towse AK, Cooke J. Prescribing incentive schemes: a useful approach? Appl. Health Econ. Health Policy 4(2), 111-117 (2005).
15. Kanavos P. Do generics offer signifcant savings to the UK National Health Service? Curr. Med. Res. Opin. 23(1), 105-116 (2007).
16. Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns-a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care 17, 179-189 (2009).
17. Smith PC and York N. Quality incentives: the case of UK general practitioners. Health Affairs 23, 112-118 (2004).
18. Roland M. Linking physicians' pay to the quality of care-a major experiment in the United Kingdom. N. Eng. J. Med. 351, 1448-1454 (2004).
19. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med. 355, 375-384 (2006).
20. MacBride-Stewart A, Elton R, Walley T. Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Family Practice 25(1), 27-32 (2008).
21. Barrett A, Riques T, Small M et al. How much will Herceptin really cost? BMJ 333, 1118-1120 (2006).
22. Delaney B, Ford AC, Forman D et al. Initial management strategies for dyspepsia. Cochrane Database Syst. Rev. (4), CD001961 (2005).
23. Yang YY, Lewis J, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24), 2947-2953 (2006).
24. Gulmez S, Holm A, Frederiksen H et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch. Intern. Med. 167, 950-955 (2007).
25. Choudry M, Soran H, Ziglam H. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium diffcile-associated disease. Q JM 101, 445-448 (2008).
26. Leaonard J, Marshall JK, Moavvedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am. J. Gastroenterol. 102, 2047-2056 (2007).
27. Hawkey C. Drugs that cause and heal peptic ulcer disease. Basic Clin. Pharm. Toxicology 105(Suppl. 1), 17 (2009).
28. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
29. Cholesterol Treatment Trialists (CTT) Collaborators. Effcacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90.056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
30. Cholesterol Treatment Trialists' (CTT) Collaborators. Effcacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).
31. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practise: executive summary. Eur. Heart J. 28, 2375-2414 (2007).
32. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial; Heart Protection Study Collaborative Group. Lancet 360, 7-22 (2002).
33. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003)
34. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J. 28, 88-136 (2007).
35. Josan K, Majumdar S, McAlister F. The effcacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178, 576-584 (2008).
36. Walley T, Folino-Gallo P, Schwabe U, van Ganse E; on behalf of the EuroMedStat group. Variations and increase use of statins across Europe: data from administrative databases. BMJ 328, 385-386 (2004).
37. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoeconomics Outcomes Res. 9, 475-484 (2009).
38. Godman B, Vlahovic-Palcevski, Laius O et al. Trends in consumption and expenditure of proton pump inhibitors (PPIs) in 20 European countries. Basic Clin. Pharm. Toxicology 105 (Suppl. 1), 37 (2009).
39. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking-an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7(3), 1-11 (2009).
40. Coombes R. GPs saved £400m in 2008 by increasing use of generic drugs. BMJ 338, 1230 (2009).
41. Barton S. Using clinical evidence. BMJ 322, 503-504 (2001).
42. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patient's care. Lancet 362, 1225-1230 (2003).
43. Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research fndings. BMJ 317, 465-468 (1998).
44. Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med. J. Aust. 172, 16-18 (2000).
45. Björnsson E, Abrahssom H, Simrén M et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 24, 945-954 (2006).
46. Forgacs I, Loganayagam A. Over prescribing proton pump inhibitors. BMJ 336, 2-3 (2008).
47. Hjemdahl P, Allhammar A, Heaton C et al SBU should investigate what is an evidence-based and cost-effective use of statins. Läkartidningen 32, 1992-1994 (2009).
48. Feely J, Bennett K. Epidemiology and economics of statin use. Ir. Med. J. 101(6), 188-191 (2008).
49. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candersartan in a primary care setting. Int. J. Clin. Pract. 61(1), 15-23 (2007).
50. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484 (2008).
51. Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int. J. Clin. Pract.63(9), 1320-1326 (2009).
52. Godman B, Wettermark B, Vlahovic-Palcevski V et al. Impact of reforms to enhance the quality and effciency of statin prescribing across 20 European countries. Basic Clin. Pharm. Toxicology 105(Suppl. 1), 35 (2009).
53. Cramer JA, Benedict A, Muszabek N et al The signifcance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 62, 76-87 (2008).
54. Kastelein J, Akdim F, Stroes E et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N. Engl. J. Med. 358(14), 1431-1443 (2008).
55. Brown GB, Taylor A. Does ENHANCE diminish confdence in lowering LDL or in ezetimibe? N. Engl. J. Med. 358(14), 1504-1507 (2008).
56. Wathen B, Dean T An evaluation of the impact of NICE guidance on GP prescribing. Br. J. Gen. Pract. 54, 103-107 (2004).